Soligenix announces achievement of two-year stability with bivalent and trivalent thermostabilized filovirus vaccines when stored at high temperatures

Vaccines stable for at least two years when stored at 40 degrees celsius / 104 degrees fahrenheit only subunit (protein) vaccine platform shown to protect against potentially lethal ebola and marburg viruses no cold chain storage and transport required as compared to other filovirus vaccines princeton, n.j. , sept. 25, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today two-year stability of its thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees celsius (104 degrees fahrenheit) when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use.
SNGX Ratings Summary
SNGX Quant Ranking